Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison

Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Hyperfine and Atossa Genetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	2	2	0	2.20
Atossa Genetics	2	0	2	1	2.40

Hyperfine presently has a consensus target price of $1.45, indicating a potential upside of 16.94%. Atossa Genetics has a consensus target price of $95.00, indicating a potential upside of 1,682.36%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Hyperfine.

Valuation & Earnings

This table compares Hyperfine and Atossa Genetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40 million	10.57	-$40.72 million	($0.44)	-2.82
Atossa Genetics	N/A	N/A	-$25.50 million	($3.60)	-1.48

Atossa Genetics has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 31.0% of Hyperfine shares are owned by company insiders. Comparatively, 9.5% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Hyperfine and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-262.29%	-95.09%	-71.11%
Atossa Genetics	N/A	-49.42%	-44.76%

Volatility and Risk

Hyperfine has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Summary

Atossa Genetics beats Hyperfine on 9 of the 13 factors compared between the two stocks.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.